Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, ...

Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating continuous monitoring. Late detection often requires major surgeries, such as ...

The global US Biomarkers Market is expected to reach US$34.3 billion by 2029 from US$20.5 billion in 2024, at a CAGR of 10.8% ...

This has been achieved in large part through two complementary but distinct types of tests: genetic screening and biomarker testing. As researchers continue to home in on the underlying genetic ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

"The Custom Assay Development Kit is a direct response to the growing demand from researchers eager to harness our cutting-edge NULISA technology to develop high-performance biomarker assays for ...

The global PD-L1 biomarker testing market is on a strong growth trajectory, rising from USD 777.2 million in 2025 to USD 1,690.8 million by 2035, at a CAGR of 8.1% during the forecast period. PD-L1 ...